Payment overview · 2025
General Payments
$79.36
5 reported records · 4 companies
Healthcare provider profile · identity verified
Steven Ritter, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Critical Care Medicine · POUGHKEEPSIE, NY · NPI 1073544292
Verified facts
What the public records show
CMS Open Payments records show Steven Ritter, MD received $79.36 in general payments during 2025 across 5 reported records.
ABBVIE INC. accounted for 41.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lumigan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.51 | 41.0% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $15.84 | 20.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $15.83 | 19.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.18 | 19.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $79.36 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $32.51 | 2 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $32.51 | 2 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $32.51 | 2 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levetiracetam | Levetiracetam | 276 | 25 |
| Enoxaparin Sodium | Enoxaparin Sodium | 241 | 21 |
| Levothyroxine Sodium | Levothyroxine Sodium | 153 | 17 |
| Eliquis | Apixaban | 147 | 11 |
| Enulose | Lactulose | 140 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 126 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 118 | 16 |
| Gabapentin | Gabapentin | 115 | 17 |
| Baclofen | Baclofen | 114 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 102 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 16 |
| Scopolamine | Scopolamine | 96 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 93 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 17 |
| Sertraline Hcl | Sertraline Hcl | 81 | 12 |
| Clonazepam | Clonazepam | 78 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 75 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 68 | 14 |
| Heparin Sodium | Heparin Sodium,porcine | 67 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 63 | suppressed |
| Xifaxan | Rifaximin | 57 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 55 | suppressed |
| Lorazepam | Lorazepam | 54 | 14 |
| Lamotrigine | Lamotrigine | 52 | suppressed |
| Epidiolex | Cannabidiol (Cbd) | 50 | suppressed |
| Metformin Hcl | Metformin Hcl | 50 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | suppressed |
| Lactulose | Lactulose | 47 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 46 | suppressed |
| Amantadine | Amantadine Hcl | 45 | suppressed |
| Mirtazapine | Mirtazapine | 45 | suppressed |
| Risperidone | Risperidone | 44 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 44 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 42 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 41 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | 11 |
| Furosemide | Furosemide | 39 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 38 | suppressed |
| Carvedilol | Carvedilol | 36 | suppressed |
| Clobazam | Clobazam | 35 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 34 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 33 | 32 |
| Lisinopril | Lisinopril | 33 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Lacosamide | Lacosamide | 32 | suppressed |
| Olanzapine | Olanzapine | 32 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 32 | suppressed |
| Constulose | Lactulose | 31 | suppressed |
| Konvomep | Omeprazole/Sodium Bicarbonate | 31 | suppressed |
| Losartan Potassium | Losartan Potassium | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 30 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Alogliptin | Alogliptin Benzoate | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 11 |
| Xcopri | Cenobamate | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Fycompa | Perampanel | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Zonisamide | Zonisamide | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Phenobarbital | Phenobarbital | 22 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 22 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 21 | suppressed |
| Levofloxacin | Levofloxacin | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 18 | 12 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 17 | 12 |
| Atrovent Hfa | Ipratropium Bromide | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Erythromycin | Erythromycin Base | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Lumigan | Bimatoprost | 14 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Nayzilam | Midazolam | 11 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $79.36 · 5 records | ABBVIE INC. | APTIMA, AVYCAZ, DALVANCE, EMBLAVEO, INSPIRE, Sunosi, TEFLARO | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error